Canakinumab in Patients With COVID-19 and Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 116 participants.
Also called NCT04510493
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 116 participants
- Registry
-
NCT04510493
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Switzerland
- Registry status
- Completed
Technical summary
Registry record NCT04510493. Randomized; double masking; primary purpose treatment. Start 2020-10-23 (actual); primary completion 2021-08-17 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Canakinumab in Patients With COVID-19 and Type 2 Diabetes
- Acronym
- CanCovDia
- Condition
- Coronavirus Infection
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Canakinumab
- Intervention (Drug)
- Placebo
- Lead sponsor
- University Hospital, Basel, Switzerland
- Collaborator
- Novartis
- Collaborator
- Swiss National Science Foundation
Record details
- Record id
cardio:ct-nct04510493- Content hash
fac51ff4a7f7e2d5d995488e488e7c7b83ac24898302353a5a78dcaa72c823b0